tetano
Editor, Senior Moderator
Ital J Pediatr
. 2021 Nov 13;47(1):225.
doi: 10.1186/s13052-021-01172-8.
Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020-21 season
Chiara Gasparini[SUP] 1 [/SUP], Miriam Acunzo[SUP] 2 [/SUP], Andrea Biuso[SUP] 2 [/SUP], Stefania Roncaglia[SUP] 2 [/SUP], Francesca Migliavacca[SUP] 2 [/SUP], Catia R Borriello[SUP] 3 [/SUP], Caterina Bertolini[SUP] 3 [/SUP], Michaela R Allen[SUP] 4 [/SUP], Annalisa Orenti[SUP] 5 [/SUP], Patrizia Boracchi[SUP] 5 [/SUP], Gian Vincenzo Zuccotti[SUP] 2 [/SUP]
Affiliations
Abstract
Background: In Italy only recently, for the 2020-21 season, has the flu vaccination been extended to all children. A quadrivalent live attenuated influenza vaccine (qLAIV) was administered to children aged 2-17 years for the first time. We registered the number and severity of adverse reactions to (Fluenz Tetra™) and the factors influencing them, evaluated uniformity of access to care and assessed the degree of satisfaction with the vaccination of both parents and health care providers, in order to improve the 2021-22 vaccination program.
Methods: On vaccination day, a questionnaire was given out to collect information about the children and their parents. Between 1 and 3 months later, the parents were contacted to record any adverse reactions following (Fluenz Tetra™) and rate the degree of satisfaction.
Results: We received data of 3226 children from 2152 families. Adverse events were reported in 24.8% of children: 80.6% mild, 18.1% moderate and 1.3% significant. The most common were rhinitis (52.5%) and fever (24.4%). Statistical analysis performed with a multiple regression model, showed that children aged 2-5 years have an increased risk of adverse events compared to both 6-10 years old (aRR 1.7, 95% CI 1.5-1.9, p < 0. 001) and 11-17 years old (aRR 1.5, 95% CI 1-2.2, p = 0.051). Most families chose to vaccinate their children to protect them and because they were concerned about Covid19. The main channel through which parents became aware of a new flu vaccination was word-of-mouth (39.8%), which occurred mostly among parents of the same school group, followed by information from the child's doctor (30.6%), the Internet (26.9%), personal research (15%), newspapers (4%), telecommunications (7.5%) and other (2.6%). Most parents (83.3%) were very satisfied and intend to vaccinate their children with qLAIV again (83.8%). The majority of operators (93%) considered the experience as excellent and are willing to repeat it (94.6%).
Conclusion: (Fluenz Tetra™) proved to be easy to administer and the degree of satisfaction was high among both health workers and parents. Considering its substantial safety profile especially in school-age children and adolescents, all these aspects make the nasal qLAIV optimal for widespread immunization. Schools offer the best setting to reach more families and physicians should be actively involved.
Keywords: Adverse events; Children; Influenza; Quadrivalent live attenuated influenza vaccine; Widespread immunization.
. 2021 Nov 13;47(1):225.
doi: 10.1186/s13052-021-01172-8.
Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020-21 season
Chiara Gasparini[SUP] 1 [/SUP], Miriam Acunzo[SUP] 2 [/SUP], Andrea Biuso[SUP] 2 [/SUP], Stefania Roncaglia[SUP] 2 [/SUP], Francesca Migliavacca[SUP] 2 [/SUP], Catia R Borriello[SUP] 3 [/SUP], Caterina Bertolini[SUP] 3 [/SUP], Michaela R Allen[SUP] 4 [/SUP], Annalisa Orenti[SUP] 5 [/SUP], Patrizia Boracchi[SUP] 5 [/SUP], Gian Vincenzo Zuccotti[SUP] 2 [/SUP]
Affiliations
- PMID: 34774062
- DOI: 10.1186/s13052-021-01172-8
Abstract
Background: In Italy only recently, for the 2020-21 season, has the flu vaccination been extended to all children. A quadrivalent live attenuated influenza vaccine (qLAIV) was administered to children aged 2-17 years for the first time. We registered the number and severity of adverse reactions to (Fluenz Tetra™) and the factors influencing them, evaluated uniformity of access to care and assessed the degree of satisfaction with the vaccination of both parents and health care providers, in order to improve the 2021-22 vaccination program.
Methods: On vaccination day, a questionnaire was given out to collect information about the children and their parents. Between 1 and 3 months later, the parents were contacted to record any adverse reactions following (Fluenz Tetra™) and rate the degree of satisfaction.
Results: We received data of 3226 children from 2152 families. Adverse events were reported in 24.8% of children: 80.6% mild, 18.1% moderate and 1.3% significant. The most common were rhinitis (52.5%) and fever (24.4%). Statistical analysis performed with a multiple regression model, showed that children aged 2-5 years have an increased risk of adverse events compared to both 6-10 years old (aRR 1.7, 95% CI 1.5-1.9, p < 0. 001) and 11-17 years old (aRR 1.5, 95% CI 1-2.2, p = 0.051). Most families chose to vaccinate their children to protect them and because they were concerned about Covid19. The main channel through which parents became aware of a new flu vaccination was word-of-mouth (39.8%), which occurred mostly among parents of the same school group, followed by information from the child's doctor (30.6%), the Internet (26.9%), personal research (15%), newspapers (4%), telecommunications (7.5%) and other (2.6%). Most parents (83.3%) were very satisfied and intend to vaccinate their children with qLAIV again (83.8%). The majority of operators (93%) considered the experience as excellent and are willing to repeat it (94.6%).
Conclusion: (Fluenz Tetra™) proved to be easy to administer and the degree of satisfaction was high among both health workers and parents. Considering its substantial safety profile especially in school-age children and adolescents, all these aspects make the nasal qLAIV optimal for widespread immunization. Schools offer the best setting to reach more families and physicians should be actively involved.
Keywords: Adverse events; Children; Influenza; Quadrivalent live attenuated influenza vaccine; Widespread immunization.